Indivior /£INDV

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Indivior

Indivior PLC, listed under the ticker symbol INDV, is a global pharmaceutical company. Founded in 2014, it primarily focuses on developing medications for the treatment of addiction and serious mental illnesses. The company operates in the pharmaceuticals sector, providing innovative treatment solutions globally.

Ticker

£INDV

Primary listing

LSE

Industry

Pharmaceuticals

Employees

1,041

ISIN

GB00BN4HT335

Indivior Metrics

BasicAdvanced
£1.4B
-
-£0.35
0.34
-

What the Analysts think about Indivior

Analyst ratings (Buy, Hold, Sell) for Indivior stock.

Bulls say / Bears say

Indivior's plan to shift its primary listing from London to New York aims to attract more U.S. investors and potentially increase its inclusion in major U.S. stock indices, reflecting its strong U.S. market presence where 85% of sales are generated. (ft.com)
The company reported robust financial performance for 2023, with $1.1 billion in sales and $223 million in adjusted net income, driven significantly by its opioid addiction treatment, Sublocade. (ft.com)
Indivior's inclusion in the U.S. Russell 2000® and 3000® Indexes as of June 30, 2025, may enhance its visibility and attract a broader investor base. (indivior.com)
Indivior issued its second profit and revenue warnings in three months due to lower than expected sales from its opioid addiction treatment, Sublocade, impacted by rapid adoption of the competing drug Brixadi. (reuters.com)
The company faced a significant 40% drop in share price and a strategic shift towards streamlining product offerings and R&D activities due to legal issues and competitive pressures. (ft.com)
Indivior lowered its profit forecast for 2024, indicating a decline in sales of its primary opioid addiction treatment, Sublocade, and decided to discontinue sales of its schizophrenia drug, Perseris, resulting in 130 job cuts. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.

Indivior Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Indivior Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £INDV

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs